Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$26.23 -1.3%	$23.28	$13.40 ▼ $26.65	$4.48B	0.7	2.02 million shs	2.21 million shs
CYTK Cytokinetics	$37.35 -1.3%	$36.14	$29.31 ▼ $59.39	$4.53B	0.64	1.59 million shs	2.16 million shs
PGEN Precigen	$4.55 -0.9%	$2.10	$0.65 ▼ $4.82	$1.37B	1.87	16.49 million shs	10.26 million shs
TGTX TG Therapeutics	$28.96 +1.4%	$33.56	$21.11 ▼ $46.48	$4.53B	1.95	2.94 million shs	1.84 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+3.30%	+6.54%	+17.46%	+19.20%	+68.70%
CYTK Cytokinetics	-0.94%	+1.37%	+3.28%	+20.79%	-32.26%
PGEN Precigen	+7.75%	+42.99%	+190.51%	+230.22%	+299.13%
TGTX TG Therapeutics	+1.03%	+0.92%	-20.62%	-19.99%	+23.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.0364 of 5 stars	3.3	2.0	0.0	3.4	4.2	2.5
CYTK Cytokinetics	3.7387 of 5 stars	3.5	1.0	4.6	3.5	0.8	0.0
PGEN Precigen	3.8437 of 5 stars	3.4	0.0	4.7	3.0	1.7	0.6
TGTX TG Therapeutics	4.407 of 5 stars	3.4	1.0	3.5	3.6	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	10.08% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$71.58	91.66% Upside
PGEN Precigen	2.80	Moderate Buy	$8.25	81.32% Upside
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	59.70% Upside

Current Analyst Ratings Breakdown

Latest PGEN, TGTX, CYTK, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PGEN Precigen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/19/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$6.00 ➝ $8.00
8/19/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.50
8/15/2025	PGEN Precigen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
8/13/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/8/2025	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.62	$0.70 per share	37.69	$4.87 per share	5.39
CYTK Cytokinetics	$18.47M	241.98	N/A	N/A	($3.08) per share	-12.13
PGEN Precigen	$3.92M	345.86	N/A	N/A	($0.12) per share	-37.92
TGTX TG Therapeutics	$329M	13.97	$0.12 per share	238.16	$1.74 per share	16.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.72	34.51	6.76	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.10	N/A	N/A	N/A	-707.17%	N/A	-45.52%	11/5/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.42	N/A	N/A	N/A	-2,868.66%	-842.83%	-78.98%	11/13/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.37	78.27	28.96	N/A	13.31%	26.05%	9.58%	11/3/2025 (Estimated)

Latest PGEN, TGTX, CYTK, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PGEN Precigen	-$0.14	-$0.11	+$0.03	-$0.09	$0.67 million	$0.86 million
8/7/2025	Q2 2025	CYTK Cytokinetics	-$1.34	-$1.12	+$0.22	-$1.12	$1.95 million	$66.77 million
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
CYTK Cytokinetics	N/A	6.76	6.76
PGEN Precigen	N/A	2.71	2.71
TGTX TG Therapeutics	0.89	3.86	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CYTK Cytokinetics	N/A
PGEN Precigen	33.51%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
CYTK Cytokinetics	2.70%
PGEN Precigen	47.10%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
CYTK Cytokinetics	250	119.66 million	116.43 million	Optionable
PGEN Precigen	190	297.97 million	157.63 million	Optionable
TGTX TG Therapeutics	290	158.67 million	141.78 million	Optionable

PGEN, TGTX, CYTK, and ACAD Headlines

Recent News About These Companies

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

August 28 at 8:00 AM | globenewswire.com

Raymond James Financial Inc. Purchases 205,111 Shares of TG Therapeutics, Inc. $TGTX

August 27 at 3:47 AM | marketbeat.com

Wellington Management Group LLP Boosts Position in TG Therapeutics, Inc. $TGTX

August 26 at 4:15 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Position Decreased by 1832 Asset Management L.P.

August 25 at 6:17 AM | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Bought by Algert Global LLC

August 23, 2025 | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Bought by Russell Investments Group Ltd.

August 23, 2025 | marketbeat.com

TG Therapeutics: Looking For The Stimulus For A Turnaround

August 20, 2025 | seekingalpha.com

Fox Run Management L.L.C. Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 19, 2025 | marketbeat.com

746,696 Shares in TG Therapeutics, Inc. $TGTX Bought by Nuveen LLC

August 19, 2025 | marketbeat.com

Invesco Ltd. Raises Position in TG Therapeutics, Inc. $TGTX

August 19, 2025 | marketbeat.com

Wealthedge Investment Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 17, 2025 | marketbeat.com

Sector Gamma AS Acquires Shares of 55,000 TG Therapeutics, Inc. (NASDAQ:TGTX)

August 17, 2025 | marketbeat.com

TG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You Think

August 16, 2025 | finance.yahoo.com

Aigen Investment Management LP Purchases Shares of 9,522 TG Therapeutics, Inc. (NASDAQ:TGTX)

August 14, 2025 | marketbeat.com

Persistent Asset Partners Ltd Has $1.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 13, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Public Sector Pension Investment Board

August 13, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Entropy Technologies LP

August 13, 2025 | marketbeat.com

Pandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 10, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Natixis Advisors LLC

August 10, 2025 | marketbeat.com

TG Therapeutics files automatic mixed securities shelf

August 9, 2025 | msn.com

Beyond the Balance Sheet: What SWOT Reveals About TG Therapeutics Inc (TGTX)

August 8, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, TGTX, CYTK, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$26.23 -0.34 (-1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$26.23 0.00 (0.00%)

As of 07:40 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Cytokinetics NASDAQ:CYTK

$37.35 -0.48 (-1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$37.17 -0.18 (-0.47%)

As of 07:43 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Precigen NASDAQ:PGEN

$4.55 -0.04 (-0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$4.57 +0.02 (+0.44%)

As of 07:59 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

TG Therapeutics NASDAQ:TGTX

$28.96 +0.39 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$28.63 -0.33 (-1.14%)

As of 07:59 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time